Affinia Therapeutics Receives FDA Fast Track and EMA Orphan Drug Designations for AFTX-201

Affinia Therapeutics has received the US Food and Drug Administration (FDA) fast track designation (FTD) for AFTX-201, a genetic medicine under investigation for treating Bcl-2-associated athanogene 3 (BAG3)-associated dilated cardiomyopathy (DCM). The European Medicines Agency (EMA) has also granted Orphan Drug designation to Affinia for AFTX-201.

AFTX-201 is being evaluated as a one-time intravenous gene therapy in adults with genetically confirmed BAG3 DCM. The therapy delivers a fully human, full-length BAG3 transgene using the company's capsid engineered for cardiac transduction at doses five to ten times lower than doses of gene therapies such as AAV9 or AAVrh74.

It is undergoing assessment in the Phase I/II UPBEAT clinical trial in BAG3 DCM patients. The single-arm, open-label, multi-centre trial is evaluating the pharmacodynamics, tolerability, safety, and preliminary efficacy of AFTX-201. It has dose-exploration and dose-expansion phases. All participants receive a single intravenous infusion at a dose supported by preclinical data. Safety is monitored over 52 weeks post-administration with additional pharmacodynamic and efficacy assessments.

The trial design incorporates preclinical proof-of-concept findings and oversight measures, including protocol stopping rules, central safety reviews, and an independent Data Safety Monitoring Board. Preclinical studies in an animal disease model demonstrated that AFTX-201 increased BAG3 protein levels in the heart and completely restored cardiac function.

The fast track designation aims to accelerate medicines that address unmet medical needs in serious conditions. Programmes, which are granted FTD, receive early and frequent feedback from the FDA during development and may submit marketing applications on a rolling basis. If criteria are met, the FDA can also grant accelerated approval or priority review, potentially reducing time to market.

The EMA grants Orphan Drug designation to encourage the development of medicines intended for the treatment of life-threatening or chronically debilitating rare conditions affecting fewer than 5 in 10,000 individuals in the European Union. This designation provides several incentives, including protocol assistance, 10-year market exclusivity upon marketing authorization, fee reductions, and other financial incentives.

BAG3 DCM is a devastating genetic heart disease caused by a mutation in the BAG3 gene and resulting in loss of heart function at a young age. The disease affects more than 70,000 patients in the Canada, E.U., U.S., and U.K. regions. The BAG3, or Bcl2-associated athanogene 3, gene encodes for a protein that is critical to the normal structure and function of heart cells. Patients with BAG3 DCM have a mutation in the BAG3 gene and a deficiency in functional BAG3 protein, resulting in early onset heart failure that progresses rapidly. Despite current standard of care, almost 25% of patients require a heart transplant.

In October 2025, Affinia Therapeutics raised $40m in a Series C funding round, led by New Enterprise Associates.